A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE DOSE ESCALATION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-07059013 AND OPEN-LABEL ASSESSMENT OF FOOD AND FORMULATION ON PHARMACOKINETICS OF PF-07059013 IN HEALTHY ADULT PARTICIPANTS
Latest Information Update: 25 Sep 2024
At a glance
- Drugs PF-07059013 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Pfizer
Most Recent Events
- 13 Jan 2022 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped: Study was terminated as it did not demonstrate sufficient pharmacological effect. Termination was not related to safety reasons.
- 13 Oct 2021 Planned End Date changed from 1 Dec 2021 to 3 Jan 2022.
- 13 Oct 2021 Planned primary completion date changed from 1 Dec 2021 to 3 Jan 2022.